Cyclodextrin‐based delivery of Annexin A1 mimetic Ac2–26 enhances anti‐inflammatory effect and prevents dengue‐induced lethality combined with antiviral therapy
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70303 ↗At a glance
Journal article in British Journal of Pharmacology, 2026. Written by Jenniffer Ramos Martins and 17 co-authors. Institution: Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil. Major MEDLINE topics: Annexin A1, Dengue, Antiviral Agents, Anti-Inflammatory Agents. 56 references. Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (original language)
Background and Purpose Severe dengue is characterised by systemic inflammation, cytokine storm, vascular leakage and haemorrhagic manifestations, largely driven by the host immune response to dengue virus (DENV) infection. Despite its burden, no licensed antivirals or host‐directed therapies are currently available. Our group has previously identified Annexin A1 (AnxA1) as an endogenous regulator of inflammation in dengue. Treatment with the AnxA1 peptidomimetic, Ac 2–26 , improved clinical outcomes in murine models of severe dengue by promoting resolution of inflammation without affecting viral control. Experimental Approach To explore new delivery strategies, we developed a novel formulation of Ac 2–26 complexed with hydroxypropyl‐β‐cyclodextrin (CDX‐Ac 2–26 ). Key Results In DENV‐2‐infected A129 mice, both intraperitoneal and oral CDX‐Ac 2–26 improved clinical scores and reversed thrombocytopenia. Notably, CDX‐Ac 2–26 reduced mast cell degranulation, MCPT‐1 plasma levels and CCL2 expression in spleen, with no effect on viral titres, indicating a host‐targeted mechanism and overcoming the anti‐inflammatory effects of the free peptide. Intraperitoneal administration achieved the same efficacy as oral dosing with only one‐third of the dose. Importantly, the combination of CDX‐Ac 2–26 with the antiviral nucleotide analogue sofosbuvir fully prevented disease and mortality in infected mice, highlighting a combinatorial effect between host‐directed and antiviral therapies. Conclusion and Implications These findings underscore the therapeutic potential of anti‐inflammatory/pro‐resolving strategies in severe dengue and support the development of CDX‐Ac 2–26 as a novel adjunctive treatment. Combining anti‐inflammatory and antiviral approaches may enhance efficacy and reduce treatment‐associated toxicity, offering a promising path for clinical translation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Chemistry, Institute of Exact Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
ORCID profiles: Felipe Rocha da Silva Santos, Mauro Martins Teixeira
Funding
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- National Institute of Science and Technology in Dengue and Host-microorganism Interaction (INCT dengue)
- The Brazilian National Science Council
- Minas Gerais Foundation for Science
Cite
APA
Martins, J. R., Batista, V. L., Ramos, L. G., Queiroz-Junior, C. M., da Fonseca, T. C. M., Dias, A. S. L., Silva, L. S., da Silva Santos, F. R., de Castro Santos, A. L., Lula, I. S., Rocha, F. E. O., Pereira, J. A. B., Lara, E. S., Souza, T. M. L., Sousa, L. P., Teixeira, M. M., Guimarães, P. P. G., & Costa, V. V. (2026). Cyclodextrin‐based delivery of Annexin A1 mimetic Ac2–26 enhances anti‐inflammatory effect and prevents dengue‐induced lethality combined with antiviral therapy. British Journal of Pharmacology. https://doi.org/10.1111/bph.70303
Vancouver
Martins JR, Batista VL, Ramos LG, Queiroz-Junior CM, da Fonseca TCM, Dias ASL, et al. Cyclodextrin‐based delivery of Annexin A1 mimetic Ac2–26 enhances anti‐inflammatory effect and prevents dengue‐induced lethality combined with antiviral therapy. British Journal of Pharmacology. 2026. doi:10.1111/bph.70303
BibTeX
@article{Martins2026,
author = {Martins, Jenniffer Ramos and Batista, Viviane Lima and Ramos, Laís Gomes and Queiroz-Junior, Celso Martins and da Fonseca, Talita Cristina Martins and Dias, Angélica Samer Lallo and Silva, Leticia Soldati and da Silva Santos, Felipe Rocha and de Castro Santos, Ana Luiza and Lula, Ivana Silva and Rocha, Felipe Emanuel Oliveira and Pereira, Jéssica Aparecida Barsalini and Lara, Edvaldo Souza and Souza, Thiago Moreno L and Sousa, Lirlândia Pires and Teixeira, Mauro Martins and Guimarães, Pedro Pires Goulart and Costa, Vivian Vasconcelos},
title = {Cyclodextrin‐based delivery of Annexin A1 mimetic Ac2–26 enhances anti‐inflammatory effect and prevents dengue‐induced lethality combined with antiviral therapy},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70303}
}
EUVIMED